GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (STU:135A) » Definitions » Cyclically Adjusted PB Ratio

SCYNEXIS (STU:135A) Cyclically Adjusted PB Ratio : 0.14 (As of Jun. 23, 2024)


View and export this data going back to 2016. Start your Free Trial

What is SCYNEXIS Cyclically Adjusted PB Ratio?

As of today (2024-06-23), SCYNEXIS's current share price is €1.767. SCYNEXIS's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €12.30. SCYNEXIS's Cyclically Adjusted PB Ratio for today is 0.14.

The historical rank and industry rank for SCYNEXIS's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:135A' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.1   Med: 0.32   Max: 0.68
Current: 0.14

During the past years, SCYNEXIS's highest Cyclically Adjusted PB Ratio was 0.68. The lowest was 0.10. And the median was 0.32.

STU:135A's Cyclically Adjusted PB Ratio is ranked better than
94.02% of 753 companies
in the Drug Manufacturers industry
Industry Median: 1.87 vs STU:135A: 0.14

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

SCYNEXIS's adjusted book value per share data for the three months ended in Mar. 2024 was €1.805. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €12.30 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


SCYNEXIS Cyclically Adjusted PB Ratio Historical Data

The historical data trend for SCYNEXIS's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SCYNEXIS Cyclically Adjusted PB Ratio Chart

SCYNEXIS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.29 0.23

SCYNEXIS Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.55 0.43 0.23 0.10

Competitive Comparison of SCYNEXIS's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SCYNEXIS's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's Cyclically Adjusted PB Ratio falls into.



SCYNEXIS Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

SCYNEXIS's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.767/12.3
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SCYNEXIS's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, SCYNEXIS's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.805/131.7762*131.7762
=1.805

Current CPI (Mar. 2024) = 131.7762.

SCYNEXIS Quarterly Data

Book Value per Share CPI Adj_Book
201406 34.127 100.560 44.721
201409 32.948 100.428 43.233
201412 31.852 99.070 42.368
201503 29.732 99.621 39.329
201506 36.381 100.684 47.616
201509 32.018 100.392 42.028
201512 27.693 99.792 36.569
201603 22.629 100.470 29.680
201606 16.670 101.688 21.602
201609 12.616 101.861 16.321
201612 13.413 101.863 17.352
201703 12.278 102.862 15.729
201706 10.641 103.349 13.568
201709 8.072 104.136 10.215
201712 6.244 104.011 7.911
201803 6.379 105.290 7.984
201806 4.852 106.317 6.014
201809 5.063 106.507 6.264
201812 5.721 105.998 7.112
201903 1.996 107.251 2.452
201906 1.689 108.070 2.060
201909 0.972 108.329 1.182
201912 1.191 108.420 1.448
202003 0.597 108.902 0.722
202006 0.537 108.767 0.651
202009 0.752 109.815 0.902
202012 0.951 109.897 1.140
202103 1.056 111.754 1.245
202106 1.159 114.631 1.332
202109 1.339 115.734 1.525
202112 1.272 117.630 1.425
202203 1.210 121.301 1.314
202206 1.320 125.017 1.391
202209 0.532 125.227 0.560
202212 0.093 125.222 0.098
202303 -0.838 127.348 -0.867
202306 2.311 128.729 2.366
202309 2.319 129.860 2.353
202312 1.798 129.419 1.831
202403 1.805 131.776 1.805

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


SCYNEXIS  (STU:135A) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


SCYNEXIS Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of SCYNEXIS's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


SCYNEXIS (STU:135A) Business Description

Traded in Other Exchanges
Address
1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.

SCYNEXIS (STU:135A) Headlines

No Headlines